Wed, Sep 17, 2014, 9:58 AM EDT - U.S. Markets close in 6 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

keysrfun 2 posts  |  Last Activity: Sep 12, 2014 1:16 PM Member since: May 13, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    chart technicals and history

    by keysrfun Sep 12, 2014 1:04 PM
    keysrfun keysrfun Sep 12, 2014 1:16 PM Flag

    first of all, dont degrade me with the "brand new noisy fella" slam. I just pointed out historical data and no company trades "on fundamental news only". "talking technicals" is also degrading. I see this board is full of people insulting each other. Why dont you point to some facts of what fundamentals caused the Jan -April slide and what brilliant news caused the run up? that would support your claim by facts instead of insults... good grief, good bye...

  • Just an observation on historical chart for AMPE. If you plot the top to bottom 10.40 to 5.07 Jan to April, then the subsequent rise to 8.67 in July. Then repeat that pattern again projecting into future, you have a bottom at 3.34 on 9/25/14 and a rise to approx 7 mid December. I note that company said news of the open label injections would be about 1 month after their 8.25.14 letter which would be approx around 25th Sept. Note the March to April bottom was rounded and took about a month to form. Thus, if this is start of bottoming process it could last a month again. Just an observation since this stock over time has repeated its chart pattern both up and down. I've been in and out several times over years. Good luck long or short. I'm on long side now.

    Sentiment: Buy

SNTA
3.7599+0.0899(+2.45%)9:57 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.